Table 1.
Patient characteristics
| CD (n = 82) | UC (n = 45) | |
|---|---|---|
| Age (median, IQR) | 15.0 (13.1–16.6) | 14.2 (11.4–16.7) |
| Males (n, %) | 43 (52 %) | 19 (42 %) |
| Months since diagnosis of IBD (median, IQR) | 26.1 (9.8–39.1) | 22.4 (7.6–43.6) |
| Current medication for IBD (n, %) | 77 (93 %) | 43 (96 %) |
| • Anti-TNF (n, %) | 32 (39 %) | 2 (4 %) |
| • Steroids (n, %) | 7 (9 %) | 9 (20 %) |
| • Thiopurine (n, %) | 36 (44 %) | 16 (36 %) |
| • Methotrexate (n, %) | 8 (10 %) | 0 (0 %) |
| • 5-ASA (n, %) | 9 (11 %) | 37 (82 %) |
| Previous IBD-related surgery (n, %) | 12 (15 %) | 1 (2 %) |
| • Perianal surgery (n, %) | 7 (8 %) | 0 (0 %) |
| • Resectional surgery (n, %) | 5 (6 %) | 1 (2 %) |
| CD: age at diagnosis (Paris classification) | ||
| • A1a 0–<10 years (n, %) | 25 (30 %) | |
| • A1b 10–<17 years (n, %) | 57 (70 %) | |
| • A2 17–40 years (n, %) | 0 (0 %) | |
| CD: locationa (Paris classification) | ||
| • L1 (n, %) | 7 (9 %) | |
| • L2 (n, %) | 24 (29 %) | |
| • L3 (n, %) | 49 (60 %) | |
| • L4a (n, %) | 34 (41 %) | |
| • L4b (n, %) | 3 (4 %) | |
| • L4ab (n, %) | 1 (1 %) | |
| CD: behavior (Paris classification) | ||
| • B1 non-structuring, non-penetrating (n, %) | 69 (84 %) | |
| • B2 structuring (n, %) | 7 (9 %) | |
| • B3 penetrating (n, %) | 5 (6 %) | |
| • B2B3 penetrating and structuring (n, %) | 1 (1 %) | |
| • p perianal disease (n, %) | 13 (16 %) | |
| CD: growth impairment (Paris classification) | ||
| • Evidence of growth delay (n, %) | 14 (17 %) | |
| CD: aPCDAI (median, IQR) | 5 (0–10) | |
| UC: extent (Paris classification) | ||
| • E1 proctitis (n, %) | 5 (11 %) | |
| • E2 left-sided disease (n, %) | 11 (24 %) | |
| • E3 extensive disease (n, %) | 6 (13 %) | |
| • E4 pancolitis (n, %) | 23 (51 %) | |
| UC: severityb (Paris classification) | ||
| • S1 ever severe (n, %) | 9 (20 %) | |
| UC: PUCAI (median, IQR) | 5 (0–15) | |
aPCDAI abbreviated Pediatric Crohn’s Disease Activity Index, CD Crohn’s disease, PUCAI Pediatric Ulcerative Colitis Activity Index, UC ulcerative colitis
aL1 distal 1/3 ileum ± limited cecal disease, L2 colonic, L3 ileocolonic, L4a upper disease proximal to ligament of Treitz, L4b upper disease distal to ligament of Treitz and proximal to distal 1/3 ileum
bDefined as ever a PUCAI ≥65 points